Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies

– ONWARD3 data show 54% of patients reached complete skin clearance (PASI 100) after 48 weeks of continuous envudeucitinib treatment – – Favorable long-term safety and tolerability profile remained consistent with previously reported data – – On track to submit a New Drug Application to FDA in 4Q 2026 – SOUTH SAN FRANCISCO, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with i